Sangamo Therapeutics, Inc. (SGMO) has disclosed a new risk, in the Capital Markets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sangamo Therapeutics, Inc. faces heightened exposure to shifting international trade policies as it relies on third-party suppliers outside the U.S. for key materials and equipment, making it vulnerable to new tariffs, sanctions and trade barriers. These measures could drive up research and development costs, disrupt supply chains and delay clinical timelines, ultimately weakening its competitive position and financing prospects.
In addition, evolving tariff and sanctions regimes increase compliance complexity and the risk of enforcement actions, while foreign retaliatory measures could limit Sangamo Therapeutics, Inc.’s market access, investment inflows and intellectual property protections abroad. The resulting macroeconomic pressures and regulatory uncertainties may materially and adversely affect its business, financial condition, results of operations and long-term growth outlook.
The average SGMO stock price target is $4.67, implying 1,791.45% upside potential.
To learn more about Sangamo Therapeutics, Inc.’s risk factors, click here.